Public funding and pricing
Public funding and pricing The Norwegian Medical Products Agency is responsible for assessing the cost-effectivness of and setting maximum prices for prescription-only-medicines.
FINOSE becomes Joint Nordic HTA-Bodies, JNHB
Published:
Switching between a reference product and a biosimilar
Published:
|
Updated:
Closer Nordic co-operation regarding more paediatric medicines
Published:
|
Updated:
Why are approved medicines not marketed or withdrawn in Norway?
Published:
|
Updated: